Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | CASP3 | P42574 | 2/20 | 0.74 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.74 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.74 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25866687 | 0.88 | SMN1; SMN2 (0.65) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL9647875 | 0.86 | SMN1; SMN2 (0.74) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL4434197 | 0.85 | MDM2 (0.67) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL4427393 | 0.85 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL4433477 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL31339958 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL4426818 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL29368114 | 0.83 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL29678523 | 0.83 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL28509330 | 0.83 | MDM2 (0.60) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| US-20060148855-A1 | Carboxamide derivatives | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1606289-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004072069-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | RAB9A 1467/4885NPC1 1228/4885SMN1; SMN2 1219/4885 |
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | RAB9A 1477/4885NPC1 784/4885SMN1; SMN2 3167/4885 |
| US-20060148855-A1 | Carboxamide derivatives | CNR2, CNR1, SUCNR1 | RAB9A 2395/4885NPC1 2461/4885SMN1; SMN2 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.